Royalty Report: Drugs, Cancer, Therapeutic – Collection: 3954


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals
  • Disease
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3954

License Grant
The Parties, one U.S. and the other Japanese, desire and intend to collaborate with respect to the Development and Commercialization of Products in the Field in the Territory.
License Property
Two pharmaceutical companies entered into a global agreement to develop and commercialize MDV3100, a investigational drug for the treatment of prostate cancer.  MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 3516

License Grant
The Licensor grants the Licensee an exclusive royalty-bearing, sub-licensable license under the Licensor Technology and sub-license under the UCLA Technology, in each case to research, develop, use, manufacture, have manufactured, sell, offer for sale, commercialize, import, and otherwise exploit Collaboration Molecules and Products in the Field in the Territory.

Subject to the terms and conditions of this Agreement, the Licensee hereby grants the Licensor a non-exclusive, non-sub-licensable solely to permit subcontractors to perform Licensor's assigned responsibilities under any Joint Development Plan, Joint Manufacturing Plan, Joint Medical Affairs Plan or Joint Commercialization Plan, royalty-free, fully-paid license under the Technology, and sub-license under the Licensor Technology and UCLA Technology licensed to the Licensee.

License Property
The Parties desire and intend to collaborate with respect to the Development and Commercialization of Products in the Field in the Territory. Field means the prevention, diagnosis and treatment of all human diseases.
Field of Use
The Global Agreement is to develop and commercialize MDV3100, the Licensor's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

IPSCIO Record ID: 27588

License Grant
The Licensor granted an exclusive worldwide license, with the right to sublicense, under certain patents and patent applications to make, have made, use, sell, offer to sell and import certain anti-androgen steroids including galeterone. In addition, the Licensor granted a first option to receive an exclusive license to its rights in certain improvements to the licensed products.
License Property
Galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate that is believed to have advantages over existing prostate cancer therapies. Galeterone disrupts the activation of the pathway through multiple mechanisms of action inhibition of the enzyme CYP17, which blocks the synthesis of testosterone; androgen receptor antagonism, which blocks the binding of testosterone or DHT with the androgen receptor; and androgen receptor degradation, which reduces the amount of androgen receptor protein in the tumor cells. The license includes rights to a U.S. patent covering compositions and methods of use of a class of compounds encompassing galeterone, which expires in 2017.
Field of Use
The Licensee exercised their option and acquired exclusive rights to licensed improvements under three amendments to the license agreement. In March 2009, the license agreement was amended to grant an exclusive license to oral prodrugs of the licensed products. In April 2012, the license agreement was amended to grant an exclusive license to compositions and methods of inducing endoplasmic reticulum stress. In October 2013, the license agreement was amended to grant an exclusive license to a patent application directed to analogs of galeterone that disrupt androgen receptor signaling by degrading the androgen receptor.

The Licensee had administered galeterone to over 250 prostate cancer patients and healthy volunteers in Phase I and Phase II clinical trials. The plans for a Phase III clinical trial are for the first half of 2015.

IPSCIO Record ID: 1617

License Grant
The Company obtains an exclusive worldwide license to the Licensed Patents, probasin gene (PG) and to practice, use or sell the Licensed Processes from Canadian University.
License Property
Licensed Patents shall mean all patent applications respecting PG (a) International PCT Application Serial No. PCT CA 9300319 filed August 9, 1993 entitled DNA Sequences of Rat Probasin Gene; and (b) all patent applications respecting PG which may be filed from time to time by University pursuant to this Agreement.
Field of Use
Field of Use shall mean human gene therapy involving the transfer of genetic material into target mammalian cells in vitro or in vivo for the purpose of intercellular drug delivery and/or treatment of a disease or medical condition.

IPSCIO Record ID: 2928

License Grant
An Australian licensor and a U.S. clinical development oncology company (majority owned by licensor) have concluded a Licence Agreement for licensee to develop and commercialize the oncology compound NV-128.
License Property
NV-128 is a cancer compound which has been shown in pre-clinical studies to promote cancer cell death in multi-drug resistant cancer cells by inducing caspase – independent DNA degradation and cancer cell death via the AKT-mTOR pathway.
Field of Use
Licensee will fund the ongoing clinical programs and is responsible for the commercial development of the drug.  Licensee is also the licensee of the licensor developed investigational anti-cancer drugs phenoxodiol and triphendiol that are currently in clinical development.

IPSCIO Record ID: 369284

License Grant
University grants Licensee and its affiliated companies and exclusive License under the Licensed Patents and a non-exclusive license under the know-how in the field of use to make, have made, use, sell, offer to sell and import Licensed Products and perform Licensed Services in the Licensed Territory. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee. Exclusive refers to Licensed Patents only. Know-how, data and other materials licensed are provided on a non-exclusive basis only.
License Property
Licensor Inventions related to 'Multiple Novel Androgen Receptor Variants as Biomarkers and Therapeutic Targets for Androgen Refractory Human Prostate Cancer' and 'Methods and Compositions Related to Prostate Cancer Therapeutics'.

Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein

Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.

Field of Use
Inventions related to certain assays to identify androgen receptor variants for use as a companion diagnostic with galeterone.

Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.

Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).

IPSCIO Record ID: 26125

License Grant
A  portion of this intellectual property is owned by the Licensor and granted to the Company through an exclusive licensing agreement with Licensor, non-profit academic medical center.
License Property
One of the curaxins from the 9-aminoacridine group is a long-known anti-infective compound known as quinacrine, which we refer to as Curaxin CBLC102. It has  been  used for over 40 years to treat malaria, osteoarthritis and autoimmune disorders. However, we have discovered new mechanisms of action for quinacrine in the area of apoptosis. Through assay testing performed at Dr. Andrei Gudkov's laboratories beginning in 2002, which included testing  in a variety of human tumor-derived cell lines representing cancers of different  tissue origin (including RCC sarcomas, prostate, breast and colon carcinomas),  we have observed that Curaxin CBLC102 behaves as a potent NF-kB suppressor and  activator of p53 in these types of cancer cells. It has favorable  pharmacological and toxicological profiles and demonstrates the anticancer  effect in transplants of human cancer cells into primates. These features make  Curaxin CBLC102 our prime IND drug candidate among other curaxins. The drug  candidate is currently in Phase II clinical trials for treatment of hormone  refractory prostate cancer.  We also intend to conduct additional Phase II  clinical trials with Curaxin CBLC102 for RCC and multiple myeloma.
Field of Use
The rights granted apply to the healthcare industry.  Licensee is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.

IPSCIO Record ID: 26022

License Grant
Two pharmaceutical companies have restructured their partnership for the global development and marketing of Nexavar (sorafenib) tablets and entered into a new agreement related to licensee's regorafenib, a late-stage oncology compound.

The Parties have agreed to resolve Litigation pursuant to a Settlement Agreement of even date herewith, pursuant to which the Parties have agreed, among other things, that Licensor will agree that regorafenib is not a Collaboration Compound under the Collaboration Agreement, and Licensee will grant Licensor certain rights related to the development and promotion of regorafenib, and pay Licensor royalties based on the sales of regorafenib together with fees for co-promotion services.

Pursuant to this agreement regarding Regorafenib, Licensor grants an exclusive, worldwide license, with the right to grant sublicenses, under the Licensor Developed IP developed pursuant to the Separate Development Program which resulted in the approval for such Separate Indication to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported, the Product for all indications.

This agreement includes non-exclusive grants back to Licensor.

These agreements also settle and dismiss all claims related to the lawsuit.

License Property
Regorafenib has shown antitumour activity in preclinical studies by inhibiting tumour growth in multiple xenograft models via anti-angiogenic and antiproliferative mechanisms. Based on these results, it is currently being investigated in clinical trials for its potential to treat patients with various tumour types.

Compound means the compound designated as regorafenib, also referred to as BAY 73-4506, together with salts and esters thereof or any other modification which would permit the use of clinical data for regorafenib to be used to establish the efficacy of the modified molecule.

Field of Use
Regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors, or GIST.

Nexavar, an oral therapy for liver cancer and the treatment of patients with advanced kidney cancer, is currently approved in more than 100 countries worldwide. It is also being evaluated in other cancers by Bayer, Onyx and other parties.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 245947

License Grant
The Foundation, not-for-profit academic medical center,  hereby grants to Licensee an exclusive license under the Licensed Rights to (a) make, have made, develop, use, import, export, distribute, market, promote, offer for sale and sell Products, (b) practice any method, process or procedure within the Licensed Patents or the Foundation Technology, and (c) otherwise exploit the Licensed Rights within the Licensed Territory for use within the Licensed Field; and to have any of the foregoing performed on its behalf by a third party.   The Parties have consented to the licensing of the Invention and Patent Rights under the License Agreement as amended by the terms set forth.
License Property
Patent Rights means all right, title and interest of the parties in, to and under any of the following
US Patent Number / Application    60/571,149
MDR Inhibitors which are the subject of the Patent Rights ('Invention').

Panacela Product shall mean the following Products developed and commercialized by Panacella
(i)   Arkil small-molecular polycyclic organic compound for systemic use to treat hormone-independent prostate tumors;
(ii)  Mobilan recombinant adenovirus of CBLB501 series for localized intratumor injection, converts the injected tumor into an efficient vaccine in situ by intratumor expression of a bacterial immunogen and its receptor; and

(iii)  Revercom nano-particle combining a chemotherapeutic drug with an inhibitor of the tumor drug resistance molecular mechanism of CBLC500 series for the treatment of tumors resistant to chemotherapy.

Foundation Technology shall mean all Foundation’s and Other Institution’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (i) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Field of Use
The Licensed Field means 0500 series modulating the androgen receptor (AR) pathway, constant activity of which is essential for growth and viability of the majority of prostate cancers, including those that have lost their dependence on androgen.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.